- Home
- KSS vs AUPH Comparison
KSS vs AUPH Comparison
Compare KSS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSS
- AUPH
- Stock Information
- Founded
- KSS 1962
- AUPH 1993
- Country
- KSS United States
- AUPH Canada
- Employees
- KSS N/A
- AUPH N/A
- Industry
- KSS Department/Specialty Retail Stores
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- KSS Consumer Discretionary
- AUPH Health Care
- Exchange
- KSS Nasdaq
- AUPH Nasdaq
- Market Cap
- KSS 1.4B
- AUPH 999.8M
- IPO Year
- KSS 1992
- AUPH 1999
- Fundamental
- Price
- KSS $7.07
- AUPH $8.18
- Analyst Decision
- KSS Sell
- AUPH Strong Buy
- Analyst Count
- KSS 12
- AUPH 2
- Target Price
- KSS $9.91
- AUPH $11.50
- AVG Volume (30 Days)
- KSS 13.8M
- AUPH 1.3M
- Earning Date
- KSS 05-29-2025
- AUPH 05-05-2025
- Dividend Yield
- KSS 23.02%
- AUPH N/A
- EPS Growth
- KSS N/A
- AUPH N/A
- EPS
- KSS 0.98
- AUPH 0.04
- Revenue
- KSS $16,221,000,000.00
- AUPH $235,133,000.00
- Revenue This Year
- KSS N/A
- AUPH $11.86
- Revenue Next Year
- KSS N/A
- AUPH $24.96
- P/E Ratio
- KSS $7.20
- AUPH $204.50
- Revenue Growth
- KSS N/A
- AUPH 33.97
- 52 Week Low
- KSS $6.04
- AUPH $4.86
- 52 Week High
- KSS $28.25
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- KSS 44.51
- AUPH 56.33
- Support Level
- KSS $6.63
- AUPH $7.92
- Resistance Level
- KSS $7.36
- AUPH $8.32
- Average True Range (ATR)
- KSS 0.67
- AUPH 0.34
- MACD
- KSS 0.17
- AUPH 0.07
- Stochastic Oscillator
- KSS 58.57
- AUPH 90.64
About KSS Kohl's Corporation
Kohl's operates about 1,176 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 26% of its 2023 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.